Alliance Pharma (APH) Price & Analysis

Compare

55 Followers

APH Stock Chart & Stats

Day’s Range― - ―

52-Week Range$32.00 - $66.20

Previous CloseN/A

Volume68.57K

Average Volume (3M)N/A

Market Cap

$355.92M

Enterprise ValueN/A

Total Cash (Recent Filing)$19.27M

Total Debt (Recent Filing)£103.13M

Price to Earnings (P/E)―

Beta0.85

Next Earnings

Sep 30, 2025

EPS Estimate

2.5

Last Dividend Ex-Date

Jun 22, 2023

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding550,105,400

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$64.75

Price Target Upside0.08% Upside

Rating ConsensusHold

Number of Analyst Covering1

Alliance Pharma News

PremiumCompany Announcements

Glazer Capital Acquires Major Stake in Alliance Pharma

3M ago

PremiumCompany Announcements

Alliance Pharma Announces Acquisition by Aegros Bidco Limited

3M ago

PremiumCompany Announcements

Alliance Pharma Releases 2024 Annual Report

3M ago

PremiumCompany Announcements

Alliance Pharma Reports Steady 2024 Results and Announces Acquisition

4M ago

PremiumCompany Announcements

Alliance Pharma’s Acquisition by Aegros Bidco Advances with Regulatory Approvals

4M ago

PremiumCompany Announcements

Alliance Pharma Announces Change in Major Holdings

4M ago

PremiumCompany Announcements

Alliance Pharma Shareholders Approve Acquisition by Aegros Bidco

4M ago

PremiumCompany Announcements

Alliance Pharma Receives Final Increased Cash Offer from Aegros Bidco

4M ago

See All GB:APH News

See All News >

Bulls Say, Bears Say

Bulls Say

AcquisitionDBAY's initial offer was raised by 20% to 62.5p, and the acquisition of Alliance is expected to complete.

Debt ManagementNet debt (£83.2m at 30 June) and leverage (1.81x at 30 June) were both a nudge better, and are expected to fall further in H2, with the company targeting c.1.5x.

Bears Say

Product PerformanceKey consumer products like Nizoral and Amberen continue to struggle and were below expectations.

Revenue DeclineRevenues declined 1% to £180.3m, which is below consensus expectations.

Supply Chain IssuesRestructuring of the China supply chain for key product Kelo-Cote is taking longer than expected.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

0.39%

Mutual Funds

― Other Institutional Investors

99.61% Public Companies and

Individual Investors

Detailed Ownership Overview >

APH FAQ

What was Alliance Pharma’s price range in the past 12 months?

Alliance Pharma lowest share price was $32.00 and its highest was $66.20 in the past 12 months.

What is Alliance Pharma’s market cap?

Alliance Pharma’s market cap is $355.92M.

When is Alliance Pharma’s upcoming earnings report date?

Alliance Pharma’s upcoming earnings report date is Sep 30, 2025 which is in 70 days.

How were Alliance Pharma’s earnings last quarter?

Currently, no data Available

Is Alliance Pharma overvalued?

According to Wall Street analysts Alliance Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alliance Pharma pay dividends?

Alliance Pharma pays a Annually dividend of $1.183 which represents an annual dividend yield of N/A. See more information on Alliance Pharma dividends here

What is Alliance Pharma’s EPS estimate?

Alliance Pharma’s EPS estimate is 2.5.

How many shares outstanding does Alliance Pharma have?

Alliance Pharma has 550,105,400 shares outstanding.

What happened to Alliance Pharma’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Alliance Pharma?

Currently, no hedge funds are holding shares in GB:APH

Alliance Pharma Stock Smart Score

Neutral

Analyst Consensus

Hold

Average Price Target:
$64.75 (0.08% Upside)

News Sentiment

Neutral

Bullish news 59%
Bearish news 100%

Fundamentals

Return on Equity

-5.04%

Trailing 12-Months

Asset Growth

-11.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alliance Pharma

Alliance Pharma (APH) is a UK-based international healthcare group that specializes in acquiring, marketing, and distributing pharmaceutical and healthcare products. The company operates in various sectors, including consumer healthcare and prescription medicines. Its core products include a wide range of well-established brands, with a focus on dermatology, oral health, and women’s health, as well as a portfolio of prescription medicines.

APH Stock 12 Month Forecast

Average Price Target

$64.75

▲(0.08%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"$33","66":"$66","41.25":"$41.3","49.5":"$49.5","57.75":"$57.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":64.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$64.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$64.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$64.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,41.25,49.5,57.75,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"May<br/>2024","9":"Sep<br/>2024","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.2,62.39615384615385,62.59230769230769,62.78846153846154,62.98461538461539,63.18076923076923,63.37692307692308,63.573076923076925,63.769230769230774,63.965384615384615,64.16153846153846,64.3576923076923,64.55384615384615,{"y":64.75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.2,62.39615384615385,62.59230769230769,62.78846153846154,62.98461538461539,63.18076923076923,63.37692307692308,63.573076923076925,63.769230769230774,63.965384615384615,64.16153846153846,64.3576923076923,64.55384615384615,{"y":64.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.2,62.39615384615385,62.59230769230769,62.78846153846154,62.98461538461539,63.18076923076923,63.37692307692308,63.573076923076925,63.769230769230774,63.965384615384615,64.16153846153846,64.3576923076923,64.55384615384615,{"y":64.75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.14,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.85,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.5,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.6,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.25,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.25,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.8,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.65,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.1,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Similar Stocks

BMK

Benchmark Holdings

―

VLG

Venture Life

―

EAH

Eco Animal Health

―

ANCR